Results 61 to 70 of about 77,446 (306)
International Journal of Cardiology: Heart & Vasculature, 2023 Background: Colchicine has anti-inflammatory properties, but its utility in improving cardiovascular outcomes has been disputed. Here, we study the impact of colchicine on cardiovascular outcomes in patients with gout with and without coronary artery ...
Muhammad U. Siddiqui +5 more
doaj
Journal of Pure and Applied Microbiology, 2017 The objective of this study was to identify and study the effect of colchicine treatment on the growth and enzyme production of Pycnoporus coccineus KKUPN1.
W. Sutthisa1 , Sanoamuang2,3
doaj +1 more source
British Journal of General Practice, 2016 Would colleagues please be aware of the devastating consequences of a significant colchicine …
openaire +3 more sources
Circulation, 2020 Inflammation has a crucial role in the progression of atherosclerosis. COLCOT (Colchicine Cardiovascular Outcome Trial) recently showed cardiovascular benefit of treatment with colchicine.1 Colchicine is an established anti-inflammatory drug, which ...
T. Opstal +9 more
semanticscholar +1 more source
Colchicine-induced myoneuropathy in a cyclosporine-treated renal transplant recipient
Kidney Research and Clinical Practice, 2013 Colchicine is a relatively safe medication that is widely used for both prevention and treatment of gout attack. However, serious adverse events, including myoneuropathy and multiorgan failure, have been reported.
Kyungmin Huh +6 more
doaj +1 more source
Cardiovascular Therapeutics, 2022 Aim. Colchicine as an anti-inflammatory drug might be effective in the treatment of atherosclerosis, an inflammatory-based condition. The aim of this systematic review and meta-analysis was to evaluate the impact of colchicine on acute coronary syndrome (
Erfan Razavi +3 more
doaj +1 more source
Relationship Between Gout Flare States and Patient‐Reported Outcomes After Allopurinol Initiation
Arthritis Care &Research, EarlyView.Objective Gout flares are the most important clinical feature of the disease. A hypothetical maximum flare occurrence in the preceding six months has been suggested to be no flares for a patient‐acceptable symptom state (PASS) and only one flare for low disease activity (LDA).
Lisa K. Stamp +6 more
wiley +1 more source
Colchicine in systemic amyloidosis. [PDF]
Annals of the Rheumatic Diseases, 1984 PubMed ID ...
AKOGLU, E, AKOGLU, T, ERKEN, E
openaire +4 more sources
Arthritis Care &Research, EarlyView.Objective The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. Methods New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an ...
Wenyan Sun +8 more
wiley +1 more source
Colchicine reduces atherosclerotic plaque vulnerability in rabbits
Atherosclerosis Plus, 2021 Background and aims: The anti-inflammatory agent colchicine is gaining interest as a treatment for coronary artery disease. However, the effects of colchicine in atherosclerotic animal models are mostly unknown. This study aimed to evaluate colchicine in
François Roubille +12 more
doaj